• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.共价KRASG12C抑制剂的化学蛋白质组学表征
ACS Med Chem Lett. 2018 May 21;9(6):557-562. doi: 10.1021/acsmedchemlett.8b00110. eCollection 2018 Jun 14.
2
Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS and ARS compounds.概念验证表明 KRAS 和 ARS 化合物的抑制剂结合能力差,并且易于形成共价加合物。
Org Biomol Chem. 2020 Apr 29;18(16):3069-3081. doi: 10.1039/d0ob00071j.
3
Applications of Reactive Cysteine Profiling.活性半胱氨酸分析的应用。
Curr Top Microbiol Immunol. 2019;420:375-417. doi: 10.1007/82_2018_120.
4
A Chemical Proteomic Probe for the Mitochondrial Pyruvate Carrier Complex.一种用于线粒体丙酮酸载体复合物的化学蛋白质组学探针。
Angew Chem Int Ed Engl. 2020 Mar 2;59(10):3896-3899. doi: 10.1002/anie.201914391. Epub 2020 Feb 11.
5
Drug Target Identification Using an iTRAQ-Based Quantitative Chemical Proteomics Approach-Based on a Target Profiling Study of Andrographolide.基于穿心莲内酯靶点分析研究,采用基于iTRAQ的定量化学蛋白质组学方法进行药物靶点鉴定。
Methods Enzymol. 2017;586:291-309. doi: 10.1016/bs.mie.2016.09.049. Epub 2016 Dec 2.
6
Reactive-cysteine profiling for drug discovery.用于药物发现的反应性半胱氨酸分析。
Curr Opin Chem Biol. 2019 Jun;50:29-36. doi: 10.1016/j.cbpa.2019.02.010. Epub 2019 Mar 18.
7
Reactive chemistry for covalent probe and therapeutic development.用于共价探针和治疗开发的反应性化学。
Trends Pharmacol Sci. 2022 Mar;43(3):249-262. doi: 10.1016/j.tips.2021.12.002. Epub 2022 Jan 6.
8
Comparison of Different Competitive Proteome Profiling Approaches in Target Identification of Covalent Inhibitors.比较不同竞争蛋白质组学方法在共价抑制剂靶标鉴定中的应用。
Chembiochem. 2022 Dec 16;23(24):e202200389. doi: 10.1002/cbic.202200389. Epub 2022 Nov 22.
9
Isotopically-Labeled Iodoacetamide-Alkyne Probes for Quantitative Cysteine-Reactivity Profiling.同位素标记碘乙酰胺-炔基探针用于定量半胱氨酸反应性分析。
Mol Pharm. 2018 Mar 5;15(3):743-749. doi: 10.1021/acs.molpharmaceut.7b00832. Epub 2017 Dec 6.
10
Cysteine-specific Chemical Proteomics: From Target Identification to Drug Discovery.半胱氨酸特异性化学蛋白质组学:从靶点鉴定到药物发现
Chimia (Aarau). 2016 Nov 30;70(11):764-767. doi: 10.2533/chimia.2016.764.

引用本文的文献

1
Strategies for Competitive Activity-Based Protein Profiling in Small Molecule Inhibitor Discovery and Characterization.基于竞争活性的蛋白质谱分析策略在小分子抑制剂发现与表征中的应用
Isr J Chem. 2023 Mar;63(3-4). doi: 10.1002/ijch.202200113. Epub 2023 Apr 14.
2
MALDI-TOF Mass Spectrometry-Based Assay for Measuring Covalent Target Engagement of KRAS G12C Inhibitors.基于 MALDI-TOF 质谱的 KRAS G12C 抑制剂共价靶标占有率测定法。
Methods Mol Biol. 2024;2797:145-157. doi: 10.1007/978-1-0716-3822-4_11.
3
AzidoTMT Enables Direct Enrichment and Highly Multiplexed Quantitation of Proteome-Wide Functional Residues.叠氮基三甲基硅烷(AzidoTMT)可直接富集和高多重定量蛋白质组范围内的功能残基。
J Proteome Res. 2023 Jul 7;22(7):2218-2231. doi: 10.1021/acs.jproteome.2c00703. Epub 2023 Jun 7.
4
Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target.对AMG510修饰蛋白进行的全基因组分析确定肿瘤抑制因子KEAP1为脱靶标。
iScience. 2023 Jan 28;26(2):106080. doi: 10.1016/j.isci.2023.106080. eCollection 2023 Feb 17.
5
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.JDQ443 的发现、临床前特征描述和早期临床活性研究,这是一种结构新颖、高效且选择性的 KRASG12C 共价口服抑制剂。
Cancer Discov. 2022 Jun 2;12(6):1500-1517. doi: 10.1158/2159-8290.CD-22-0158.
6
Chemoproteomic methods for covalent drug discovery.化学生物学蛋白质组学方法用于共价药物发现。
Chem Soc Rev. 2021 Aug 2;50(15):8361-8381. doi: 10.1039/d1cs00231g.
7
Reactive-cysteine profiling for drug discovery.用于药物发现的反应性半胱氨酸分析。
Curr Opin Chem Biol. 2019 Jun;50:29-36. doi: 10.1016/j.cbpa.2019.02.010. Epub 2019 Mar 18.

本文引用的文献

1
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.针对 KRAS 突变癌症的共价 G12C 特异性抑制剂。
Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006.
2
Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.Ras Binder 诱导 GTP 和 GDP 状态下的变构 II 口袋。
Cell Chem Biol. 2017 Dec 21;24(12):1455-1466.e14. doi: 10.1016/j.chembiol.2017.08.025. Epub 2017 Oct 12.
3
Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in reticulon 4 that impairs ER morphology and cancer pathogenicity.基于化学蛋白质组学的共价配体筛选揭示了网织红细胞蛋白4中的一个半胱氨酸热点,该热点会损害内质网形态和癌症致病性。
Chem Commun (Camb). 2017 Jun 29;53(53):7234-7237. doi: 10.1039/c7cc01480e.
4
A Perspective on the Kinetics of Covalent and Irreversible Inhibition.关于共价和不可逆抑制动力学的观点。
SLAS Discov. 2017 Jan;22(1):3-20. doi: 10.1177/1087057116671509. Epub 2016 Oct 5.
5
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.用靶向非活性状态的小分子选择性抑制致癌性KRAS输出
Cancer Discov. 2016 Mar;6(3):316-29. doi: 10.1158/2159-8290.CD-15-1105. Epub 2016 Jan 6.
6
Identifying compound efficacy targets in phenotypic drug discovery.在表型药物发现中鉴定化合物疗效靶点。
Drug Discov Today. 2016 Jan;21(1):82-89. doi: 10.1016/j.drudis.2015.08.001. Epub 2015 Aug 10.
7
A Caged Electrophilic Probe for Global Analysis of Cysteine Reactivity in Living Cells.一种用于活细胞中半胱氨酸反应性全局分析的笼状亲电探针。
J Am Chem Soc. 2015 Jun 10;137(22):7087-90. doi: 10.1021/jacs.5b04350. Epub 2015 Jun 1.
8
Know your target, know your molecule.了解你的靶点,了解你的分子。
Nat Chem Biol. 2015 Jun;11(6):368-72. doi: 10.1038/nchembio.1813.
9
Drugging the undruggable RAS: Mission possible?靶向不可成药的 RAS:可能完成的任务?
Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17.
10
A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.评估共价激酶抑制剂对蛋白质组选择性的路线图。
Nat Chem Biol. 2014 Sep;10(9):760-767. doi: 10.1038/nchembio.1582. Epub 2014 Jul 13.

共价KRASG12C抑制剂的化学蛋白质组学表征

Chemical Proteomic Characterization of a Covalent KRASG12C Inhibitor.

作者信息

Wijeratne Aruna, Xiao Junpeng, Reutter Christopher, Furness Kelly W, Leon Rebecca, Zia-Ebrahimi Mohammad, Cavitt Rachel N, Strelow John M, Van Horn Robert D, Peng Sheng-Bin, Barda David A, Engler Thomas A, Chalmers Michael J

机构信息

Discovery Chemistry Research and Technologies and Oncology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, United States.

出版信息

ACS Med Chem Lett. 2018 May 21;9(6):557-562. doi: 10.1021/acsmedchemlett.8b00110. eCollection 2018 Jun 14.

DOI:10.1021/acsmedchemlett.8b00110
PMID:29937982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6004567/
Abstract

The KRASG12C protein product is an attractive, yet challenging, target for small molecule inhibition. One option for therapeutic intervention is to design small molecule ligands capable of binding to and inactivating KRASG12C via formation of a covalent bond to the sulfhydryl group of cysteine 12. In order to better understand the cellular off-target interactions of , a covalent KRASG12C inhibitor, we have completed a series of complementary chemical proteomics experiments in H358 cells. A new thiol reactive probe (TRP) was designed and used to construct a cellular target occupancy assay for KRASG12C. In addition, the thiol reactive probes allowed us to profile potential off-target interactions of with over 3200 cysteine residues. In order to complement the TRP data we designed , an alkyne containing version of , to serve as bait in competitive chemical proteomics experiments. Herein, we describe and compare data from both the TRP and the click chemistry probe pull down experiments.

摘要

KRASG12C蛋白产物是小分子抑制的一个有吸引力但具有挑战性的靶点。治疗干预的一种选择是设计能够通过与半胱氨酸12的巯基形成共价键来结合并使KRASG12C失活的小分子配体。为了更好地理解共价KRASG12C抑制剂的细胞脱靶相互作用,我们在H358细胞中完成了一系列互补的化学蛋白质组学实验。设计了一种新的硫醇反应性探针(TRP),并用于构建KRASG12C的细胞靶点占有率测定。此外,硫醇反应性探针使我们能够分析与超过3200个半胱氨酸残基的潜在脱靶相互作用。为了补充TRP数据,我们设计了一种含炔烃的版本作为竞争性化学蛋白质组学实验的诱饵。在此,我们描述并比较了TRP和点击化学探针下拉实验的数据。